PHIO Phio Pharmaceuticals Corp.

RXi Pharmaceuticals Corp is principally engaged in developing therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which addresses significant unmet medical needs.

$0.72  +0.02 (3.24%)
As of 05/26/2022 16:00:01 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  11/19/2018
Outstanding shares:  13,658,722
Average volume:  553,504
Market cap:   $9,561,105
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.51
PS ratio:   0.00
Return on equity:   -64.38%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy